The study involves testing epcoritamab, administered subcutaneously, in combination with oral and intravenous anti-neoplastic agents. These include drugs like lenalidomide, ibrutinib, and polatuzumab ...

The study tests the combination of two drugs: Venetoclax, an oral tablet, and Azacitidine, which can be administered as an oral tablet or via subcutaneous or intravenous injection.

AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the company published its Phase 3 TEMPLE study results, which were positive.

Study results show 51% of patients treated with the AbbVie drug developed peripheral neuropathy; 11% of those cases were classified as Grade 3. This complication led 13% of trial participants to ...

AbbVie Inc ABBV on Wednesday released topline results from its Phase 3 TEMPLE study evaluating the tolerability, safety, and efficacy of atogepant (QULIPTA/AQUIPTA, 60 mg once daily) compared to ...

AbbVie is on track to submit the New Drug Application to the FDA in 2025. Last month, AbbVie reported two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults ...

The US Food and Drug Administration (FDA) has approved two oncology drugs: MSD’s Welireg (belzutifan) and AbbVie’s Emrelis (telisotuzumab vedotin-tllv). The decisions, announced on 14 May ...

AbbVie's study also met all secondary goals, with 64.1% pati. The study's main goal was for the company's drug Qulipta, also known as Aquipta in Europe, ...

AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the company published its Phase 3 TEMPLE study results, which were positive.